Although all of the tested targeted fluorescence contrast agents have properties useful for labeling of CTCs, thus far, none has exhibited the required high specificity. This resulted in some labeling of non-cancer blood cells, which presented false-positive CTC counts. Improved contrast agent design and multiplexed use of more than one contrast agent may improve this specificity.
Pace et al. (Tue,) studied this question.